Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) EBITDA (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported EBITDA over the past 9 years, most recently at -$8.0 million for Q4 2023.

  • For Q4 2023, EBITDA rose 25.78% year-over-year to -$8.0 million; the TTM value through Dec 2023 reached -$44.5 million, down 4.88%, while the annual FY2024 figure was $6.3 million, 114.19% up from the prior year.
  • EBITDA for Q4 2023 was -$8.0 million at Corbus Pharmaceuticals Holdings, up from -$10.0 million in the prior quarter.
  • Over five years, EBITDA peaked at $1.7 million in Q2 2019 and troughed at -$38.1 million in Q2 2020.
  • A 5-year average of -$16.6 million and a median of -$14.6 million in 2021 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: surged 113.76% in 2019 and later plummeted 2334.64% in 2020.
  • Year by year, EBITDA stood at -$27.2 million in 2019, then increased by 23.46% to -$20.8 million in 2020, then soared by 51.96% to -$10.0 million in 2021, then fell by 8.0% to -$10.8 million in 2022, then rose by 25.78% to -$8.0 million in 2023.
  • Business Quant data shows EBITDA for CRBP at -$8.0 million in Q4 2023, -$10.0 million in Q3 2023, and -$8.7 million in Q2 2023.